These results indicated that Cdr1as could improve cisplatin sensitivity of ovarian cancer cells, and can act as a molecular sponge for mir-1270, impairing the inhibitory effect of miRNAs on downstream target genes SCAI. This evidence concerns the gene LINC00632 and ovarian carcinoma.